Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 8/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | DCK | P27707 | 6/20 | 0.39 |
| ▸ | POLG | P54098 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11965625 | 1.00 | AHCY (0.53) | AHCYALBADORA2BDCKPOLG | |
| SCHEMBL2803551 | 1.00 | AHCY (0.53) | AHCYALBADORA2BDCKPOLG | |
| SCHEMBL10172065 | 0.86 | ALB (0.52) | AHCYALBDCKPOLG | |
| SCHEMBL10171790 | 0.86 | ALB (0.52) | AHCYALBDCKPOLG | |
| SCHEMBL16629489 | 0.85 | AHCY (0.49) | AHCYALBADORA2B | |
| SCHEMBL16300447 | 0.85 | ALB (0.51) | AHCYALBDCKPOLG | |
| SCHEMBL21275614 | 0.85 | AHCY (0.49) | AHCYALBADORA2B | |
| SCHEMBL3950815 | 0.83 | ALB (0.54) | ALBDCKPOLG | |
| SCHEMBL599302 | 0.83 | ALB (0.54) | ALBDCKPOLG | |
| SCHEMBL599301 | 0.83 | ALB (0.54) | ALBDCKPOLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2018-10-16 | — | — | US | disclosed |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | GILEAD SCIENCES, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8242120-B2 | Carbocyclic compounds and methods for treating emerging disease, including influenza and Venezuela equine encephalitis virus | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2251015-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | Pharmasset, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20100144664-A1 | CARBOCYCLIC COMPOUNDS AND METHODS FOR TREATING EMERGING DISEASE, INCLUDING INFLUENZA AND VENEZUELA EQUINE ENCEPHALITIS VIRUS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (GA) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | SLC29A1, PNP, SLC29A2 | AHCY 3554/4885ALB 3294/4885ADORA2B 142/4885 |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, SLC29A2, PNP | AHCY 3562/4885ALB 3735/4885ADORA2B 67/4885 |
| US-20100144664-A1 | CARBOCYCLIC COMPOUNDS AND METHODS FOR TREATING EMERGING DISEASE, INCLUDING INFLUENZA AND VENEZUELA EQUINE ENCEPHALITIS VIRUS | HTR3C, APOBEC3C, CUL5 | AHCY 100/4885ALB 2716/4885ADORA2B 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.